nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—P-Glycoprotein Inhibitors—Everolimus—kidney cancer	0.232	1	CiPCiCtD
Crizotinib—lung cancer—kidney cancer	0.192	1	CtDrD
Crizotinib—ROS1—kidney cancer	0.0607	0.321	CbGaD
Crizotinib—AURKA—kidney cancer	0.0333	0.176	CbGaD
Crizotinib—MET—kidney cancer	0.0325	0.172	CbGaD
Crizotinib—IGF1R—kidney cancer	0.0307	0.163	CbGaD
Crizotinib—ALK—kidney cancer	0.0279	0.148	CbGaD
Crizotinib—LIMK2—Pazopanib—kidney cancer	0.00953	0.036	CbGbCtD
Crizotinib—MUSK—Sorafenib—kidney cancer	0.00765	0.0289	CbGbCtD
Crizotinib—CDK7—Sorafenib—kidney cancer	0.00765	0.0289	CbGbCtD
Crizotinib—BMPR1B—Pazopanib—kidney cancer	0.00757	0.0286	CbGbCtD
Crizotinib—TNK1—Erlotinib—kidney cancer	0.0068	0.0257	CbGbCtD
Crizotinib—JAK3—Erlotinib—kidney cancer	0.0068	0.0257	CbGbCtD
Crizotinib—TAOK3—Pazopanib—kidney cancer	0.00633	0.0239	CbGbCtD
Crizotinib—PLK4—Pazopanib—kidney cancer	0.00633	0.0239	CbGbCtD
Crizotinib—TIE1—Sorafenib—kidney cancer	0.00553	0.0209	CbGbCtD
Crizotinib—TAOK2—Sorafenib—kidney cancer	0.00553	0.0209	CbGbCtD
Crizotinib—MAP3K2—Pazopanib—kidney cancer	0.00547	0.0207	CbGbCtD
Crizotinib—LTK—Erlotinib—kidney cancer	0.0054	0.0204	CbGbCtD
Crizotinib—LYN—Pazopanib—kidney cancer	0.00484	0.0183	CbGbCtD
Crizotinib—EPHB6—Pazopanib—kidney cancer	0.00484	0.0183	CbGbCtD
Crizotinib—SLK—Erlotinib—kidney cancer	0.00452	0.0171	CbGbCtD
Crizotinib—TNK1—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—RPS6KB1—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—TBK1—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—MAP4K2—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—STK4—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—MAP3K12—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—STK3—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—TYK2—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—MERTK—Sunitinib—kidney cancer	0.00448	0.0169	CbGbCtD
Crizotinib—STK10—Pazopanib—kidney cancer	0.00435	0.0164	CbGbCtD
Crizotinib—CSF1R—Pazopanib—kidney cancer	0.00435	0.0164	CbGbCtD
Crizotinib—LCK—Pazopanib—kidney cancer	0.00396	0.0149	CbGbCtD
Crizotinib—FLT3—Erlotinib—kidney cancer	0.00391	0.0148	CbGbCtD
Crizotinib—ABCB1—kidney cancer	0.0038	0.0201	CbGaD
Crizotinib—MAP3K19—Pazopanib—kidney cancer	0.00364	0.0137	CbGbCtD
Crizotinib—JAK2—Sunitinib—kidney cancer	0.00356	0.0134	CbGbCtD
Crizotinib—BMP2K—Sunitinib—kidney cancer	0.00356	0.0134	CbGbCtD
Crizotinib—PTK2B—Sunitinib—kidney cancer	0.00356	0.0134	CbGbCtD
Crizotinib—TYRO3—Sunitinib—kidney cancer	0.00356	0.0134	CbGbCtD
Crizotinib—NUAK2—Sunitinib—kidney cancer	0.00356	0.0134	CbGbCtD
Crizotinib—AXL—Sunitinib—kidney cancer	0.00356	0.0134	CbGbCtD
Crizotinib—ALK—Sunitinib—kidney cancer	0.00356	0.0134	CbGbCtD
Crizotinib—MAP4K1—Sunitinib—kidney cancer	0.00356	0.0134	CbGbCtD
Crizotinib—EPHA6—Erlotinib—kidney cancer	0.00345	0.013	CbGbCtD
Crizotinib—AURKA—Doxorubicin—kidney cancer	0.00335	0.0127	CbGbCtD
Crizotinib—FLT3—Sorafenib—kidney cancer	0.00318	0.012	CbGbCtD
Crizotinib—STK10—Erlotinib—kidney cancer	0.0031	0.0117	CbGbCtD
Crizotinib—ABL2—Erlotinib—kidney cancer	0.0031	0.0117	CbGbCtD
Crizotinib—MAP3K3—Sunitinib—kidney cancer	0.00298	0.0112	CbGbCtD
Crizotinib—YES1—Sunitinib—kidney cancer	0.00298	0.0112	CbGbCtD
Crizotinib—TAOK3—Sunitinib—kidney cancer	0.00298	0.0112	CbGbCtD
Crizotinib—NTRK1—Sunitinib—kidney cancer	0.00298	0.0112	CbGbCtD
Crizotinib—MAP4K5—Sunitinib—kidney cancer	0.00298	0.0112	CbGbCtD
Crizotinib—SLK—Sunitinib—kidney cancer	0.00298	0.0112	CbGbCtD
Crizotinib—PLK4—Sunitinib—kidney cancer	0.00298	0.0112	CbGbCtD
Crizotinib—EPHB6—Sorafenib—kidney cancer	0.00281	0.0106	CbGbCtD
Crizotinib—EPHA6—Sorafenib—kidney cancer	0.00281	0.0106	CbGbCtD
Crizotinib—MAP3K19—Erlotinib—kidney cancer	0.0026	0.0098	CbGbCtD
Crizotinib—FGR—Sunitinib—kidney cancer	0.00257	0.00972	CbGbCtD
Crizotinib—FLT3—Sunitinib—kidney cancer	0.00257	0.00972	CbGbCtD
Crizotinib—MAP3K2—Sunitinib—kidney cancer	0.00257	0.00972	CbGbCtD
Crizotinib—IRAK1—Sunitinib—kidney cancer	0.00257	0.00972	CbGbCtD
Crizotinib—CSF1R—Sorafenib—kidney cancer	0.00252	0.00953	CbGbCtD
Crizotinib—STK10—Sorafenib—kidney cancer	0.00252	0.00953	CbGbCtD
Crizotinib—EPHB6—Sunitinib—kidney cancer	0.00227	0.00859	CbGbCtD
Crizotinib—BLK—Sunitinib—kidney cancer	0.00227	0.00859	CbGbCtD
Crizotinib—ABL1—Erlotinib—kidney cancer	0.00224	0.00847	CbGbCtD
Crizotinib—STK10—renal vein—kidney cancer	0.00224	0.0893	CbGeAlD
Crizotinib—MAP3K19—Sorafenib—kidney cancer	0.00211	0.00797	CbGbCtD
Crizotinib—STK10—Sunitinib—kidney cancer	0.00204	0.00772	CbGbCtD
Crizotinib—CSF1R—Sunitinib—kidney cancer	0.00204	0.00772	CbGbCtD
Crizotinib—MAP3K19—Sunitinib—kidney cancer	0.00171	0.00646	CbGbCtD
Crizotinib—STK10—renal artery—kidney cancer	0.00151	0.06	CbGeAlD
Crizotinib—CYP3A5—Temsirolimus—kidney cancer	0.000757	0.00286	CbGbCtD
Crizotinib—INSRR—renal system—kidney cancer	0.000662	0.0264	CbGeAlD
Crizotinib—INSRR—kidney—kidney cancer	0.00064	0.0255	CbGeAlD
Crizotinib—ABCB1—Temsirolimus—kidney cancer	0.000493	0.00186	CbGbCtD
Crizotinib—CYP3A4—Everolimus—kidney cancer	0.000437	0.00165	CbGbCtD
Crizotinib—CYP3A4—Temsirolimus—kidney cancer	0.000295	0.00112	CbGbCtD
Crizotinib—PRKD1—nephron tubule—kidney cancer	0.000294	0.0117	CbGeAlD
Crizotinib—NEK9—renal system—kidney cancer	0.000293	0.0117	CbGeAlD
Crizotinib—CYP3A5—Erlotinib—kidney cancer	0.000284	0.00107	CbGbCtD
Crizotinib—NEK9—kidney—kidney cancer	0.000283	0.0113	CbGeAlD
Crizotinib—PRKD1—renal system—kidney cancer	0.000267	0.0107	CbGeAlD
Crizotinib—SIK2—renal system—kidney cancer	0.000264	0.0105	CbGeAlD
Crizotinib—NEK9—gonad—kidney cancer	0.000263	0.0105	CbGeAlD
Crizotinib—CYP3A5—Paclitaxel—kidney cancer	0.00026	0.000982	CbGbCtD
Crizotinib—ABCB1—Pazopanib—kidney cancer	0.000259	0.000978	CbGbCtD
Crizotinib—PRKD1—kidney—kidney cancer	0.000258	0.0103	CbGeAlD
Crizotinib—PRKD3—renal system—kidney cancer	0.000257	0.0102	CbGeAlD
Crizotinib—PRKD3—kidney—kidney cancer	0.000248	0.0099	CbGeAlD
Crizotinib—PRKD1—gonad—kidney cancer	0.00024	0.00956	CbGeAlD
Crizotinib—ABCB1—Dactinomycin—kidney cancer	0.000237	0.000894	CbGbCtD
Crizotinib—DSTYK—cortex of kidney—kidney cancer	0.000236	0.00941	CbGeAlD
Crizotinib—CYP3A5—Sorafenib—kidney cancer	0.000231	0.000872	CbGbCtD
Crizotinib—PRKD3—gonad—kidney cancer	0.00023	0.00919	CbGeAlD
Crizotinib—CYP3A5—Vincristine—kidney cancer	0.000224	0.000846	CbGbCtD
Crizotinib—MET—renal system—kidney cancer	0.000222	0.00886	CbGeAlD
Crizotinib—CDK7—renal system—kidney cancer	0.000215	0.00857	CbGeAlD
Crizotinib—MET—kidney—kidney cancer	0.000215	0.00857	CbGeAlD
Crizotinib—MAPK7—gonad—kidney cancer	0.000213	0.00849	CbGeAlD
Crizotinib—ACVR1B—renal system—kidney cancer	0.000205	0.00819	CbGeAlD
Crizotinib—ACVR1B—kidney—kidney cancer	0.000199	0.00792	CbGeAlD
Crizotinib—CASK—Temsirolimus—Everolimus—kidney cancer	0.000198	0.226	CbGdCrCtD
Crizotinib—ABCB1—Gemcitabine—kidney cancer	0.000187	0.000707	CbGbCtD
Crizotinib—CYP3A5—Sunitinib—kidney cancer	0.000187	0.000706	CbGbCtD
Crizotinib—ABCB1—Erlotinib—kidney cancer	0.000185	0.000698	CbGbCtD
Crizotinib—ACVR1B—gonad—kidney cancer	0.000184	0.00734	CbGeAlD
Crizotinib—TESK1—nephron tubule—kidney cancer	0.000181	0.0072	CbGeAlD
Crizotinib—EPHA6—gonad—kidney cancer	0.000176	0.00701	CbGeAlD
Crizotinib—IGF1R—renal system—kidney cancer	0.000175	0.00696	CbGeAlD
Crizotinib—PLK4—gonad—kidney cancer	0.000174	0.00692	CbGeAlD
Crizotinib—NUAK2—nephron tubule—kidney cancer	0.000171	0.00683	CbGeAlD
Crizotinib—FER—cortex of kidney—kidney cancer	0.000171	0.00682	CbGeAlD
Crizotinib—ACVR1—nephron tubule—kidney cancer	0.00017	0.00678	CbGeAlD
Crizotinib—ABCB1—Paclitaxel—kidney cancer	0.000169	0.000639	CbGbCtD
Crizotinib—IGF1R—kidney—kidney cancer	0.000169	0.00673	CbGeAlD
Crizotinib—AURKA—renal system—kidney cancer	0.000166	0.0066	CbGeAlD
Crizotinib—TESK1—renal system—kidney cancer	0.000164	0.00655	CbGeAlD
Crizotinib—TYRO3—gonad—kidney cancer	0.000163	0.0065	CbGeAlD
Crizotinib—FER—gonad—kidney cancer	0.000163	0.0065	CbGeAlD
Crizotinib—FER—cardiac atrium—kidney cancer	0.000163	0.00649	CbGeAlD
Crizotinib—AURKA—kidney—kidney cancer	0.00016	0.00638	CbGeAlD
Crizotinib—STK3—cortex of kidney—kidney cancer	0.00016	0.00638	CbGeAlD
Crizotinib—IGF1R—gonad—kidney cancer	0.000157	0.00624	CbGeAlD
Crizotinib—CYP3A4—Pazopanib—kidney cancer	0.000155	0.000586	CbGbCtD
Crizotinib—TESK1—cortex of kidney—kidney cancer	0.000155	0.00616	CbGeAlD
Crizotinib—ACVR1—renal system—kidney cancer	0.000155	0.00616	CbGeAlD
Crizotinib—RIPK2—nephron tubule—kidney cancer	0.000154	0.00612	CbGeAlD
Crizotinib—TIE1—cardiac atrium—kidney cancer	0.000152	0.00607	CbGeAlD
Crizotinib—ABCB1—Sorafenib—kidney cancer	0.00015	0.000567	CbGbCtD
Crizotinib—ACVR1—kidney—kidney cancer	0.000149	0.00596	CbGeAlD
Crizotinib—AURKA—gonad—kidney cancer	0.000148	0.00592	CbGeAlD
Crizotinib—ABCB1—Vinblastine—kidney cancer	0.000148	0.00056	CbGbCtD
Crizotinib—TESK1—gonad—kidney cancer	0.000147	0.00587	CbGeAlD
Crizotinib—LIMK2—cortex of kidney—kidney cancer	0.000147	0.00586	CbGeAlD
Crizotinib—TESK1—cardiac atrium—kidney cancer	0.000147	0.00586	CbGeAlD
Crizotinib—NUAK2—cortex of kidney—kidney cancer	0.000147	0.00584	CbGeAlD
Crizotinib—ABCB1—Vincristine—kidney cancer	0.000146	0.000551	CbGbCtD
Crizotinib—MAP3K2—nephron tubule—kidney cancer	0.000146	0.00581	CbGeAlD
Crizotinib—ACVR1—cortex of kidney—kidney cancer	0.000146	0.0058	CbGeAlD
Crizotinib—PTK2—nephron tubule—kidney cancer	0.000143	0.00569	CbGeAlD
Crizotinib—TBK1—nephron tubule—kidney cancer	0.000143	0.00569	CbGeAlD
Crizotinib—TYK2—nephron tubule—kidney cancer	0.000142	0.00565	CbGeAlD
Crizotinib—PTK2B—renal system—kidney cancer	0.000141	0.00561	CbGeAlD
Crizotinib—LIMK2—gonad—kidney cancer	0.00014	0.00559	CbGeAlD
Crizotinib—IRAK1—nephron tubule—kidney cancer	0.00014	0.00557	CbGeAlD
Crizotinib—FLT3—gonad—kidney cancer	0.000139	0.00553	CbGeAlD
Crizotinib—MAP3K12—gonad—kidney cancer	0.000139	0.00553	CbGeAlD
Crizotinib—MAP3K12—cardiac atrium—kidney cancer	0.000138	0.00552	CbGeAlD
Crizotinib—ACVR1—cardiac atrium—kidney cancer	0.000138	0.00552	CbGeAlD
Crizotinib—PTK2B—kidney—kidney cancer	0.000136	0.00543	CbGeAlD
Crizotinib—STK35—gonad—kidney cancer	0.000136	0.00541	CbGeAlD
Crizotinib—STK35—cardiac atrium—kidney cancer	0.000136	0.00541	CbGeAlD
Crizotinib—SLK—nephron tubule—kidney cancer	0.000131	0.00521	CbGeAlD
Crizotinib—BMP2K—gonad—kidney cancer	0.000131	0.00521	CbGeAlD
Crizotinib—EPHB4—nephron tubule—kidney cancer	0.00013	0.00517	CbGeAlD
Crizotinib—TBK1—renal system—kidney cancer	0.00013	0.00517	CbGeAlD
Crizotinib—PTK2—renal system—kidney cancer	0.00013	0.00517	CbGeAlD
Crizotinib—TYK2—renal system—kidney cancer	0.000129	0.00513	CbGeAlD
Crizotinib—CYP3A4—urine—kidney cancer	0.000128	0.0051	CbGeAlD
Crizotinib—EPHA2—nephron tubule—kidney cancer	0.000127	0.00508	CbGeAlD
Crizotinib—PTK2B—gonad—kidney cancer	0.000126	0.00503	CbGeAlD
Crizotinib—PTK2—kidney—kidney cancer	0.000125	0.005	CbGeAlD
Crizotinib—TBK1—kidney—kidney cancer	0.000125	0.005	CbGeAlD
Crizotinib—RIPK2—cardiac atrium—kidney cancer	0.000125	0.00499	CbGeAlD
Crizotinib—RPS6KB1—renal system—kidney cancer	0.000125	0.00497	CbGeAlD
Crizotinib—TYK2—kidney—kidney cancer	0.000124	0.00496	CbGeAlD
Crizotinib—MAP3K3—nephron tubule—kidney cancer	0.000124	0.00495	CbGeAlD
Crizotinib—PTK2—cortex of kidney—kidney cancer	0.000122	0.00487	CbGeAlD
Crizotinib—TBK1—cortex of kidney—kidney cancer	0.000122	0.00487	CbGeAlD
Crizotinib—ABCB1—Sunitinib—kidney cancer	0.000122	0.00046	CbGbCtD
Crizotinib—TYK2—cortex of kidney—kidney cancer	0.000121	0.00483	CbGeAlD
Crizotinib—EPHA4—gonad—kidney cancer	0.000121	0.00483	CbGeAlD
Crizotinib—EPHA4—cardiac atrium—kidney cancer	0.000121	0.00482	CbGeAlD
Crizotinib—RPS6KB1—kidney—kidney cancer	0.000121	0.00481	CbGeAlD
Crizotinib—IRAK1—cortex of kidney—kidney cancer	0.00012	0.00477	CbGeAlD
Crizotinib—MAP3K2—gonad—kidney cancer	0.000119	0.00473	CbGeAlD
Crizotinib—EPHB4—renal system—kidney cancer	0.000118	0.0047	CbGeAlD
Crizotinib—RPS6KB1—cortex of kidney—kidney cancer	0.000117	0.00468	CbGeAlD
Crizotinib—JAK2—renal system—kidney cancer	0.000117	0.00467	CbGeAlD
Crizotinib—TBK1—gonad—kidney cancer	0.000116	0.00463	CbGeAlD
Crizotinib—PTK2—gonad—kidney cancer	0.000116	0.00463	CbGeAlD
Crizotinib—AXL—cortex of kidney—kidney cancer	0.000116	0.00463	CbGeAlD
Crizotinib—TBK1—cardiac atrium—kidney cancer	0.000116	0.00463	CbGeAlD
Crizotinib—TYK2—cardiac atrium—kidney cancer	0.000115	0.0046	CbGeAlD
Crizotinib—YES1—nephron tubule—kidney cancer	0.000115	0.00457	CbGeAlD
Crizotinib—EPHB4—kidney—kidney cancer	0.000114	0.00455	CbGeAlD
Crizotinib—JAK2—kidney—kidney cancer	0.000113	0.00452	CbGeAlD
Crizotinib—TAOK3—nephron tubule—kidney cancer	0.000113	0.00451	CbGeAlD
Crizotinib—TEK—renal system—kidney cancer	0.000113	0.0045	CbGeAlD
Crizotinib—SLK—cortex of kidney—kidney cancer	0.000112	0.00446	CbGeAlD
Crizotinib—RPS6KB1—cardiac atrium—kidney cancer	0.000112	0.00445	CbGeAlD
Crizotinib—EPHB4—cortex of kidney—kidney cancer	0.000111	0.00443	CbGeAlD
Crizotinib—AXL—gonad—kidney cancer	0.000111	0.00441	CbGeAlD
Crizotinib—CYP3A4—Erlotinib—kidney cancer	0.000111	0.000418	CbGbCtD
Crizotinib—AXL—cardiac atrium—kidney cancer	0.000111	0.00441	CbGeAlD
Crizotinib—JAK2—cortex of kidney—kidney cancer	0.00011	0.0044	CbGeAlD
Crizotinib—TEK—kidney—kidney cancer	0.000109	0.00435	CbGeAlD
Crizotinib—SLK—cardiac atrium—kidney cancer	0.000106	0.00424	CbGeAlD
Crizotinib—MAP3K3—cortex of kidney—kidney cancer	0.000106	0.00424	CbGeAlD
Crizotinib—TEK—cortex of kidney—kidney cancer	0.000106	0.00424	CbGeAlD
Crizotinib—MAP4K5—cortex of kidney—kidney cancer	0.000106	0.00424	CbGeAlD
Crizotinib—EPHB4—cardiac atrium—kidney cancer	0.000106	0.00421	CbGeAlD
Crizotinib—JAK2—gonad—kidney cancer	0.000105	0.00419	CbGeAlD
Crizotinib—JAK2—cardiac atrium—kidney cancer	0.000105	0.00418	CbGeAlD
Crizotinib—YES1—renal system—kidney cancer	0.000104	0.00416	CbGeAlD
Crizotinib—EPHA2—cardiac atrium—kidney cancer	0.000104	0.00413	CbGeAlD
Crizotinib—STK10—renal system—kidney cancer	0.000103	0.00412	CbGeAlD
Crizotinib—TAOK3—renal system—kidney cancer	0.000103	0.0041	CbGeAlD
Crizotinib—EPHB6—cortex of kidney—kidney cancer	0.000102	0.00405	CbGeAlD
Crizotinib—CYP3A4—Paclitaxel—kidney cancer	0.000101	0.000383	CbGbCtD
Crizotinib—MAP3K3—gonad—kidney cancer	0.000101	0.00404	CbGeAlD
Crizotinib—MAP4K5—gonad—kidney cancer	0.000101	0.00404	CbGeAlD
Crizotinib—TEK—cardiac atrium—kidney cancer	0.000101	0.00403	CbGeAlD
Crizotinib—MAP4K5—cardiac atrium—kidney cancer	0.000101	0.00403	CbGeAlD
Crizotinib—MAP3K3—cardiac atrium—kidney cancer	0.000101	0.00403	CbGeAlD
Crizotinib—YES1—kidney—kidney cancer	0.000101	0.00402	CbGeAlD
Crizotinib—SRC—renal system—kidney cancer	0.0001	0.004	CbGeAlD
Crizotinib—STK10—kidney—kidney cancer	9.99e-05	0.00398	CbGeAlD
Crizotinib—TAOK3—kidney—kidney cancer	9.95e-05	0.00397	CbGeAlD
Crizotinib—YES1—cortex of kidney—kidney cancer	9.82e-05	0.00391	CbGeAlD
Crizotinib—SRC—kidney—kidney cancer	9.7e-05	0.00387	CbGeAlD
Crizotinib—TAOK3—cortex of kidney—kidney cancer	9.69e-05	0.00386	CbGeAlD
Crizotinib—EPHB6—cardiac atrium—kidney cancer	9.66e-05	0.00385	CbGeAlD
Crizotinib—YES1—gonad—kidney cancer	9.35e-05	0.00373	CbGeAlD
Crizotinib—YES1—cardiac atrium—kidney cancer	9.34e-05	0.00372	CbGeAlD
Crizotinib—STK10—gonad—kidney cancer	9.27e-05	0.00369	CbGeAlD
Crizotinib—TAOK3—cardiac atrium—kidney cancer	9.22e-05	0.00368	CbGeAlD
Crizotinib—ABCB1—Doxorubicin—kidney cancer	9.11e-05	0.000344	CbGbCtD
Crizotinib—CYP3A4—Sorafenib—kidney cancer	9e-05	0.00034	CbGbCtD
Crizotinib—SRC—gonad—kidney cancer	9e-05	0.00359	CbGeAlD
Crizotinib—SRC—cardiac atrium—kidney cancer	8.98e-05	0.00358	CbGeAlD
Crizotinib—CYP3A4—Vinblastine—kidney cancer	8.89e-05	0.000336	CbGbCtD
Crizotinib—CYP3A4—Vincristine—kidney cancer	8.74e-05	0.00033	CbGbCtD
Crizotinib—CSF1R—gonad—kidney cancer	8.08e-05	0.00322	CbGeAlD
Crizotinib—CSF1R—cardiac atrium—kidney cancer	8.07e-05	0.00322	CbGeAlD
Crizotinib—ABL1—nephron tubule—kidney cancer	7.83e-05	0.00312	CbGeAlD
Crizotinib—AURKA—Sirolimus—Everolimus—kidney cancer	7.66e-05	0.0872	CbGdCrCtD
Crizotinib—AURKA—Temsirolimus—Everolimus—kidney cancer	7.66e-05	0.0872	CbGdCrCtD
Crizotinib—AURKA—Sirolimus—Temsirolimus—kidney cancer	7.66e-05	0.0872	CbGdCrCtD
Crizotinib—CYP3A4—Sunitinib—kidney cancer	7.29e-05	0.000275	CbGbCtD
Crizotinib—ABL1—renal system—kidney cancer	7.12e-05	0.00284	CbGeAlD
Crizotinib—ABL1—kidney—kidney cancer	6.88e-05	0.00274	CbGeAlD
Crizotinib—ABL1—cortex of kidney—kidney cancer	6.7e-05	0.00267	CbGeAlD
Crizotinib—ABL1—gonad—kidney cancer	6.38e-05	0.00255	CbGeAlD
Crizotinib—ABL1—cardiac atrium—kidney cancer	6.38e-05	0.00254	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—kidney cancer	5.99e-05	0.0683	CbGdCrCtD
Crizotinib—CYP3A4—Doxorubicin—kidney cancer	5.46e-05	0.000206	CbGbCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—kidney cancer	4.83e-05	0.055	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—kidney cancer	4.83e-05	0.055	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—kidney cancer	4.83e-05	0.055	CbGdCrCtD
Crizotinib—CYP3A5—nephron tubule—kidney cancer	4.58e-05	0.00183	CbGeAlD
Crizotinib—CYP3A5—renal system—kidney cancer	4.17e-05	0.00166	CbGeAlD
Crizotinib—CYP3A5—kidney—kidney cancer	4.03e-05	0.00161	CbGeAlD
Crizotinib—CYP3A5—cortex of kidney—kidney cancer	3.92e-05	0.00156	CbGeAlD
Crizotinib—Muscular weakness—Capecitabine—kidney cancer	3.35e-05	0.000738	CcSEcCtD
Crizotinib—Constipation—Erlotinib—kidney cancer	3.34e-05	0.000737	CcSEcCtD
Crizotinib—Shock—Sunitinib—kidney cancer	3.33e-05	0.000734	CcSEcCtD
Crizotinib—Nervous system disorder—Sunitinib—kidney cancer	3.32e-05	0.000732	CcSEcCtD
Crizotinib—Skin disorder—Sunitinib—kidney cancer	3.28e-05	0.000725	CcSEcCtD
Crizotinib—Vomiting—Pazopanib—kidney cancer	3.26e-05	0.000719	CcSEcCtD
Crizotinib—Bradycardia—Paclitaxel—kidney cancer	3.26e-05	0.000718	CcSEcCtD
Crizotinib—Anaemia—Vincristine—kidney cancer	3.24e-05	0.000715	CcSEcCtD
Crizotinib—Rash—Pazopanib—kidney cancer	3.23e-05	0.000713	CcSEcCtD
Crizotinib—Nausea—Temsirolimus—kidney cancer	3.23e-05	0.000713	CcSEcCtD
Crizotinib—Dermatitis—Pazopanib—kidney cancer	3.23e-05	0.000713	CcSEcCtD
Crizotinib—Oedema—Dactinomycin—kidney cancer	3.2e-05	0.000706	CcSEcCtD
Crizotinib—Body temperature increased—Everolimus—kidney cancer	3.2e-05	0.000706	CcSEcCtD
Crizotinib—Fluid retention—Doxorubicin—kidney cancer	3.2e-05	0.000706	CcSEcCtD
Crizotinib—Hypoaesthesia—Paclitaxel—kidney cancer	3.18e-05	0.000702	CcSEcCtD
Crizotinib—Infection—Dactinomycin—kidney cancer	3.18e-05	0.000702	CcSEcCtD
Crizotinib—Neuropathy—Doxorubicin—kidney cancer	3.16e-05	0.000698	CcSEcCtD
Crizotinib—Urinary tract disorder—Paclitaxel—kidney cancer	3.16e-05	0.000697	CcSEcCtD
Crizotinib—Oedema peripheral—Paclitaxel—kidney cancer	3.15e-05	0.000695	CcSEcCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—kidney cancer	3.15e-05	0.0359	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—kidney cancer	3.15e-05	0.0359	CbGdCrCtD
Crizotinib—Leukopenia—Vincristine—kidney cancer	3.14e-05	0.000692	CcSEcCtD
Crizotinib—Urethral disorder—Paclitaxel—kidney cancer	3.13e-05	0.000692	CcSEcCtD
Crizotinib—Dyspnoea—Sorafenib—kidney cancer	3.13e-05	0.000691	CcSEcCtD
Crizotinib—CYP3A4—renal system—kidney cancer	3.13e-05	0.00125	CbGeAlD
Crizotinib—Dyspepsia—Sorafenib—kidney cancer	3.09e-05	0.000683	CcSEcCtD
Crizotinib—Body temperature increased—Erlotinib—kidney cancer	3.09e-05	0.000681	CcSEcCtD
Crizotinib—Visual impairment—Paclitaxel—kidney cancer	3.08e-05	0.00068	CcSEcCtD
Crizotinib—Anaemia—Gemcitabine—kidney cancer	3.07e-05	0.000678	CcSEcCtD
Crizotinib—Neutropenia—Capecitabine—kidney cancer	3.07e-05	0.000676	CcSEcCtD
Crizotinib—Decreased appetite—Sorafenib—kidney cancer	3.05e-05	0.000674	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Capecitabine—kidney cancer	3.05e-05	0.000672	CcSEcCtD
Crizotinib—Nausea—Pazopanib—kidney cancer	3.05e-05	0.000672	CcSEcCtD
Crizotinib—Paraesthesia—Sunitinib—kidney cancer	3.04e-05	0.00067	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Sorafenib—kidney cancer	3.03e-05	0.000669	CcSEcCtD
Crizotinib—Fatigue—Sorafenib—kidney cancer	3.03e-05	0.000669	CcSEcCtD
Crizotinib—CYP3A4—kidney—kidney cancer	3.02e-05	0.00121	CbGeAlD
Crizotinib—Dyspnoea—Sunitinib—kidney cancer	3.01e-05	0.000665	CcSEcCtD
Crizotinib—Constipation—Sorafenib—kidney cancer	3.01e-05	0.000663	CcSEcCtD
Crizotinib—Eye disorder—Paclitaxel—kidney cancer	2.99e-05	0.000659	CcSEcCtD
Crizotinib—Dyspepsia—Sunitinib—kidney cancer	2.98e-05	0.000657	CcSEcCtD
Crizotinib—Leukopenia—Gemcitabine—kidney cancer	2.98e-05	0.000657	CcSEcCtD
Crizotinib—Cardiac disorder—Paclitaxel—kidney cancer	2.97e-05	0.000655	CcSEcCtD
Crizotinib—Weight decreased—Capecitabine—kidney cancer	2.97e-05	0.000654	CcSEcCtD
Crizotinib—Pneumonia—Capecitabine—kidney cancer	2.94e-05	0.000649	CcSEcCtD
Crizotinib—Decreased appetite—Sunitinib—kidney cancer	2.94e-05	0.000649	CcSEcCtD
Crizotinib—Infestation NOS—Capecitabine—kidney cancer	2.92e-05	0.000645	CcSEcCtD
Crizotinib—Infestation—Capecitabine—kidney cancer	2.92e-05	0.000645	CcSEcCtD
Crizotinib—Sepsis—Doxorubicin—kidney cancer	2.92e-05	0.000645	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Sunitinib—kidney cancer	2.92e-05	0.000644	CcSEcCtD
Crizotinib—Asthenia—Vinblastine—kidney cancer	2.92e-05	0.000643	CcSEcCtD
Crizotinib—Fatigue—Sunitinib—kidney cancer	2.92e-05	0.000643	CcSEcCtD
Crizotinib—Asthenia—Everolimus—kidney cancer	2.9e-05	0.000641	CcSEcCtD
Crizotinib—Constipation—Sunitinib—kidney cancer	2.89e-05	0.000638	CcSEcCtD
Crizotinib—Mediastinal disorder—Paclitaxel—kidney cancer	2.88e-05	0.000636	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Gemcitabine—kidney cancer	2.87e-05	0.0327	CbGdCrCtD
Crizotinib—Neuropathy peripheral—Capecitabine—kidney cancer	2.87e-05	0.000632	CcSEcCtD
Crizotinib—Oedema—Vincristine—kidney cancer	2.86e-05	0.000631	CcSEcCtD
Crizotinib—Arrhythmia—Paclitaxel—kidney cancer	2.86e-05	0.00063	CcSEcCtD
Crizotinib—Infection—Vincristine—kidney cancer	2.84e-05	0.000627	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—kidney cancer	2.81e-05	0.00062	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	2.81e-05	0.00062	CcSEcCtD
Crizotinib—Nervous system disorder—Vincristine—kidney cancer	2.8e-05	0.000619	CcSEcCtD
Crizotinib—Asthenia—Erlotinib—kidney cancer	2.8e-05	0.000618	CcSEcCtD
Crizotinib—Hepatic function abnormal—Doxorubicin—kidney cancer	2.8e-05	0.000617	CcSEcCtD
Crizotinib—Malnutrition—Paclitaxel—kidney cancer	2.78e-05	0.000614	CcSEcCtD
Crizotinib—Decreased appetite—Dactinomycin—kidney cancer	2.78e-05	0.000614	CcSEcCtD
Crizotinib—Diarrhoea—Vinblastine—kidney cancer	2.78e-05	0.000614	CcSEcCtD
Crizotinib—Body temperature increased—Sorafenib—kidney cancer	2.78e-05	0.000613	CcSEcCtD
Crizotinib—Diarrhoea—Everolimus—kidney cancer	2.77e-05	0.000611	CcSEcCtD
Crizotinib—Hepatobiliary disease—Capecitabine—kidney cancer	2.76e-05	0.00061	CcSEcCtD
Crizotinib—Fatigue—Dactinomycin—kidney cancer	2.76e-05	0.000609	CcSEcCtD
Crizotinib—Dysgeusia—Paclitaxel—kidney cancer	2.73e-05	0.000601	CcSEcCtD
Crizotinib—Hepatic failure—Doxorubicin—kidney cancer	2.72e-05	0.0006	CcSEcCtD
Crizotinib—Oedema—Gemcitabine—kidney cancer	2.71e-05	0.000599	CcSEcCtD
Crizotinib—Infection—Gemcitabine—kidney cancer	2.7e-05	0.000595	CcSEcCtD
Crizotinib—Dizziness—Vinblastine—kidney cancer	2.69e-05	0.000593	CcSEcCtD
Crizotinib—Dizziness—Everolimus—kidney cancer	2.68e-05	0.000591	CcSEcCtD
Crizotinib—Body temperature increased—Sunitinib—kidney cancer	2.67e-05	0.00059	CcSEcCtD
Crizotinib—Diarrhoea—Erlotinib—kidney cancer	2.67e-05	0.00059	CcSEcCtD
Crizotinib—Bradycardia—Capecitabine—kidney cancer	2.67e-05	0.000589	CcSEcCtD
Crizotinib—Nervous system disorder—Gemcitabine—kidney cancer	2.66e-05	0.000587	CcSEcCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	2.65e-05	0.0302	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—kidney cancer	2.65e-05	0.0302	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—kidney cancer	2.65e-05	0.0302	CbGdCrCtD
Crizotinib—Skin disorder—Gemcitabine—kidney cancer	2.64e-05	0.000582	CcSEcCtD
Crizotinib—Vision blurred—Paclitaxel—kidney cancer	2.62e-05	0.000579	CcSEcCtD
Crizotinib—Hypoaesthesia—Capecitabine—kidney cancer	2.61e-05	0.000576	CcSEcCtD
Crizotinib—Urinary tract disorder—Capecitabine—kidney cancer	2.59e-05	0.000572	CcSEcCtD
Crizotinib—Oedema peripheral—Capecitabine—kidney cancer	2.58e-05	0.00057	CcSEcCtD
Crizotinib—Vomiting—Vinblastine—kidney cancer	2.58e-05	0.00057	CcSEcCtD
Crizotinib—Dizziness—Erlotinib—kidney cancer	2.58e-05	0.00057	CcSEcCtD
Crizotinib—Vomiting—Everolimus—kidney cancer	2.57e-05	0.000568	CcSEcCtD
Crizotinib—Anaemia—Paclitaxel—kidney cancer	2.57e-05	0.000568	CcSEcCtD
Crizotinib—Urethral disorder—Capecitabine—kidney cancer	2.57e-05	0.000568	CcSEcCtD
Crizotinib—Paraesthesia—Vincristine—kidney cancer	2.57e-05	0.000567	CcSEcCtD
Crizotinib—Rash—Everolimus—kidney cancer	2.55e-05	0.000563	CcSEcCtD
Crizotinib—Dermatitis—Everolimus—kidney cancer	2.55e-05	0.000563	CcSEcCtD
Crizotinib—Body temperature increased—Dactinomycin—kidney cancer	2.53e-05	0.000558	CcSEcCtD
Crizotinib—Visual impairment—Capecitabine—kidney cancer	2.53e-05	0.000558	CcSEcCtD
Crizotinib—Asthenia—Sorafenib—kidney cancer	2.52e-05	0.000556	CcSEcCtD
Crizotinib—Syncope—Paclitaxel—kidney cancer	2.5e-05	0.000551	CcSEcCtD
Crizotinib—Leukopenia—Paclitaxel—kidney cancer	2.49e-05	0.00055	CcSEcCtD
Crizotinib—Decreased appetite—Vincristine—kidney cancer	2.49e-05	0.000549	CcSEcCtD
Crizotinib—Vomiting—Erlotinib—kidney cancer	2.48e-05	0.000548	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Vincristine—kidney cancer	2.47e-05	0.000545	CcSEcCtD
Crizotinib—Fatigue—Vincristine—kidney cancer	2.47e-05	0.000544	CcSEcCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—kidney cancer	2.47e-05	0.0281	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—kidney cancer	2.47e-05	0.0281	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—kidney cancer	2.47e-05	0.0281	CbGdCrCtD
Crizotinib—Rash—Erlotinib—kidney cancer	2.46e-05	0.000543	CcSEcCtD
Crizotinib—Dermatitis—Erlotinib—kidney cancer	2.46e-05	0.000543	CcSEcCtD
Crizotinib—Eye disorder—Capecitabine—kidney cancer	2.45e-05	0.000541	CcSEcCtD
Crizotinib—Loss of consciousness—Paclitaxel—kidney cancer	2.45e-05	0.00054	CcSEcCtD
Crizotinib—Constipation—Vincristine—kidney cancer	2.45e-05	0.00054	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—kidney cancer	2.44e-05	0.00054	CcSEcCtD
Crizotinib—Paraesthesia—Gemcitabine—kidney cancer	2.44e-05	0.000538	CcSEcCtD
Crizotinib—ABCB1—nephron tubule—kidney cancer	2.44e-05	0.000971	CbGeAlD
Crizotinib—Cardiac disorder—Capecitabine—kidney cancer	2.44e-05	0.000537	CcSEcCtD
Crizotinib—Asthenia—Sunitinib—kidney cancer	2.43e-05	0.000535	CcSEcCtD
Crizotinib—Dyspnoea—Gemcitabine—kidney cancer	2.42e-05	0.000534	CcSEcCtD
Crizotinib—Nausea—Vinblastine—kidney cancer	2.41e-05	0.000533	CcSEcCtD
Crizotinib—Nausea—Everolimus—kidney cancer	2.4e-05	0.000531	CcSEcCtD
Crizotinib—Diarrhoea—Sorafenib—kidney cancer	2.4e-05	0.000531	CcSEcCtD
Crizotinib—Mediastinal disorder—Capecitabine—kidney cancer	2.36e-05	0.000522	CcSEcCtD
Crizotinib—Face oedema—Doxorubicin—kidney cancer	2.36e-05	0.000521	CcSEcCtD
Crizotinib—Decreased appetite—Gemcitabine—kidney cancer	2.36e-05	0.00052	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	2.35e-05	0.000519	CcSEcCtD
Crizotinib—Arrhythmia—Capecitabine—kidney cancer	2.34e-05	0.000517	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Gemcitabine—kidney cancer	2.34e-05	0.000517	CcSEcCtD
Crizotinib—Fatigue—Gemcitabine—kidney cancer	2.34e-05	0.000516	CcSEcCtD
Crizotinib—Dizziness—Sorafenib—kidney cancer	2.32e-05	0.000513	CcSEcCtD
Crizotinib—Constipation—Gemcitabine—kidney cancer	2.32e-05	0.000512	CcSEcCtD
Crizotinib—Nausea—Erlotinib—kidney cancer	2.32e-05	0.000512	CcSEcCtD
Crizotinib—Diarrhoea—Sunitinib—kidney cancer	2.31e-05	0.000511	CcSEcCtD
Crizotinib—Asthenia—Dactinomycin—kidney cancer	2.3e-05	0.000507	CcSEcCtD
Crizotinib—Malnutrition—Capecitabine—kidney cancer	2.28e-05	0.000504	CcSEcCtD
Crizotinib—Oedema—Paclitaxel—kidney cancer	2.27e-05	0.000501	CcSEcCtD
Crizotinib—Body temperature increased—Vincristine—kidney cancer	2.26e-05	0.000499	CcSEcCtD
Crizotinib—Infection—Paclitaxel—kidney cancer	2.26e-05	0.000498	CcSEcCtD
Crizotinib—Dysgeusia—Capecitabine—kidney cancer	2.24e-05	0.000494	CcSEcCtD
Crizotinib—Dizziness—Sunitinib—kidney cancer	2.24e-05	0.000493	CcSEcCtD
Crizotinib—Shock—Paclitaxel—kidney cancer	2.23e-05	0.000493	CcSEcCtD
Crizotinib—Vomiting—Sorafenib—kidney cancer	2.23e-05	0.000493	CcSEcCtD
Crizotinib—Nervous system disorder—Paclitaxel—kidney cancer	2.23e-05	0.000492	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—kidney cancer	2.23e-05	0.000491	CcSEcCtD
Crizotinib—Rash—Sorafenib—kidney cancer	2.22e-05	0.000489	CcSEcCtD
Crizotinib—ABCB1—renal system—kidney cancer	2.21e-05	0.000883	CbGeAlD
Crizotinib—Dermatitis—Sorafenib—kidney cancer	2.21e-05	0.000488	CcSEcCtD
Crizotinib—Skin disorder—Paclitaxel—kidney cancer	2.21e-05	0.000487	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	2.2e-05	0.000486	CcSEcCtD
Crizotinib—Diarrhoea—Dactinomycin—kidney cancer	2.19e-05	0.000483	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	2.16e-05	0.000476	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—kidney cancer	2.16e-05	0.000476	CcSEcCtD
Crizotinib—Vision blurred—Capecitabine—kidney cancer	2.15e-05	0.000475	CcSEcCtD
Crizotinib—Vomiting—Sunitinib—kidney cancer	2.15e-05	0.000474	CcSEcCtD
Crizotinib—Body temperature increased—Gemcitabine—kidney cancer	2.14e-05	0.000473	CcSEcCtD
Crizotinib—ABCB1—kidney—kidney cancer	2.14e-05	0.000853	CbGeAlD
Crizotinib—Rash—Sunitinib—kidney cancer	2.13e-05	0.00047	CcSEcCtD
Crizotinib—Dermatitis—Sunitinib—kidney cancer	2.13e-05	0.00047	CcSEcCtD
Crizotinib—Anaemia—Capecitabine—kidney cancer	2.11e-05	0.000466	CcSEcCtD
Crizotinib—Nausea—Sorafenib—kidney cancer	2.09e-05	0.000461	CcSEcCtD
Crizotinib—ABCB1—cortex of kidney—kidney cancer	2.08e-05	0.000831	CbGeAlD
Crizotinib—Asthenia—Vincristine—kidney cancer	2.05e-05	0.000453	CcSEcCtD
Crizotinib—Syncope—Capecitabine—kidney cancer	2.05e-05	0.000452	CcSEcCtD
Crizotinib—Leukopenia—Capecitabine—kidney cancer	2.04e-05	0.000451	CcSEcCtD
Crizotinib—Paraesthesia—Paclitaxel—kidney cancer	2.04e-05	0.00045	CcSEcCtD
Crizotinib—Vomiting—Dactinomycin—kidney cancer	2.04e-05	0.000449	CcSEcCtD
Crizotinib—Dyspnoea—Paclitaxel—kidney cancer	2.03e-05	0.000447	CcSEcCtD
Crizotinib—Rash—Dactinomycin—kidney cancer	2.02e-05	0.000445	CcSEcCtD
Crizotinib—Nausea—Sunitinib—kidney cancer	2.01e-05	0.000443	CcSEcCtD
Crizotinib—Loss of consciousness—Capecitabine—kidney cancer	2.01e-05	0.000443	CcSEcCtD
Crizotinib—Dyspepsia—Paclitaxel—kidney cancer	2e-05	0.000441	CcSEcCtD
Crizotinib—ABCB1—gonad—kidney cancer	1.99e-05	0.000791	CbGeAlD
Crizotinib—Neutropenia—Doxorubicin—kidney cancer	1.98e-05	0.000436	CcSEcCtD
Crizotinib—Decreased appetite—Paclitaxel—kidney cancer	1.97e-05	0.000436	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—kidney cancer	1.96e-05	0.000433	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.96e-05	0.000433	CcSEcCtD
Crizotinib—Fatigue—Paclitaxel—kidney cancer	1.96e-05	0.000432	CcSEcCtD
Crizotinib—Diarrhoea—Vincristine—kidney cancer	1.96e-05	0.000432	CcSEcCtD
Crizotinib—Asthenia—Gemcitabine—kidney cancer	1.95e-05	0.00043	CcSEcCtD
Crizotinib—Constipation—Paclitaxel—kidney cancer	1.94e-05	0.000429	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.93e-05	0.000426	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—kidney cancer	1.91e-05	0.000422	CcSEcCtD
Crizotinib—Nausea—Dactinomycin—kidney cancer	1.9e-05	0.00042	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—kidney cancer	1.9e-05	0.000418	CcSEcCtD
Crizotinib—Dizziness—Vincristine—kidney cancer	1.89e-05	0.000417	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—kidney cancer	1.88e-05	0.000416	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—kidney cancer	1.88e-05	0.000416	CcSEcCtD
Crizotinib—Oedema—Capecitabine—kidney cancer	1.86e-05	0.000411	CcSEcCtD
Crizotinib—Diarrhoea—Gemcitabine—kidney cancer	1.86e-05	0.00041	CcSEcCtD
Crizotinib—Infection—Capecitabine—kidney cancer	1.85e-05	0.000409	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—kidney cancer	1.85e-05	0.000408	CcSEcCtD
Crizotinib—Shock—Capecitabine—kidney cancer	1.83e-05	0.000405	CcSEcCtD
Crizotinib—Nervous system disorder—Capecitabine—kidney cancer	1.83e-05	0.000403	CcSEcCtD
Crizotinib—Vomiting—Vincristine—kidney cancer	1.82e-05	0.000401	CcSEcCtD
Crizotinib—Skin disorder—Capecitabine—kidney cancer	1.81e-05	0.0004	CcSEcCtD
Crizotinib—Rash—Vincristine—kidney cancer	1.8e-05	0.000398	CcSEcCtD
Crizotinib—Dermatitis—Vincristine—kidney cancer	1.8e-05	0.000398	CcSEcCtD
Crizotinib—Body temperature increased—Paclitaxel—kidney cancer	1.8e-05	0.000396	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—kidney cancer	1.78e-05	0.000393	CcSEcCtD
Crizotinib—Vomiting—Gemcitabine—kidney cancer	1.73e-05	0.000381	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—kidney cancer	1.72e-05	0.00038	CcSEcCtD
Crizotinib—Rash—Gemcitabine—kidney cancer	1.71e-05	0.000378	CcSEcCtD
Crizotinib—Dermatitis—Gemcitabine—kidney cancer	1.71e-05	0.000377	CcSEcCtD
Crizotinib—Nausea—Vincristine—kidney cancer	1.7e-05	0.000375	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—kidney cancer	1.68e-05	0.000371	CcSEcCtD
Crizotinib—Paraesthesia—Capecitabine—kidney cancer	1.67e-05	0.000369	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—kidney cancer	1.67e-05	0.000369	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—kidney cancer	1.67e-05	0.000368	CcSEcCtD
Crizotinib—Dyspnoea—Capecitabine—kidney cancer	1.66e-05	0.000367	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—kidney cancer	1.66e-05	0.000366	CcSEcCtD
Crizotinib—Dyspepsia—Capecitabine—kidney cancer	1.64e-05	0.000362	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—kidney cancer	1.63e-05	0.00036	CcSEcCtD
Crizotinib—Asthenia—Paclitaxel—kidney cancer	1.63e-05	0.00036	CcSEcCtD
Crizotinib—Decreased appetite—Capecitabine—kidney cancer	1.62e-05	0.000358	CcSEcCtD
Crizotinib—Nausea—Gemcitabine—kidney cancer	1.61e-05	0.000356	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Capecitabine—kidney cancer	1.61e-05	0.000355	CcSEcCtD
Crizotinib—Fatigue—Capecitabine—kidney cancer	1.61e-05	0.000355	CcSEcCtD
Crizotinib—Constipation—Capecitabine—kidney cancer	1.59e-05	0.000352	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—kidney cancer	1.58e-05	0.000349	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—kidney cancer	1.57e-05	0.000346	CcSEcCtD
Crizotinib—Diarrhoea—Paclitaxel—kidney cancer	1.55e-05	0.000343	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—kidney cancer	1.52e-05	0.000336	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—kidney cancer	1.51e-05	0.000333	CcSEcCtD
Crizotinib—Dizziness—Paclitaxel—kidney cancer	1.5e-05	0.000331	CcSEcCtD
Crizotinib—Body temperature increased—Capecitabine—kidney cancer	1.47e-05	0.000325	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—kidney cancer	1.47e-05	0.000325	CcSEcCtD
Crizotinib—Vomiting—Paclitaxel—kidney cancer	1.44e-05	0.000319	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—kidney cancer	1.44e-05	0.000318	CcSEcCtD
Crizotinib—Rash—Paclitaxel—kidney cancer	1.43e-05	0.000316	CcSEcCtD
Crizotinib—Dermatitis—Paclitaxel—kidney cancer	1.43e-05	0.000316	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—kidney cancer	1.39e-05	0.000306	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—kidney cancer	1.36e-05	0.0003	CcSEcCtD
Crizotinib—Nausea—Paclitaxel—kidney cancer	1.35e-05	0.000298	CcSEcCtD
Crizotinib—Asthenia—Capecitabine—kidney cancer	1.34e-05	0.000295	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—kidney cancer	1.32e-05	0.000291	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—kidney cancer	1.32e-05	0.000291	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—kidney cancer	1.29e-05	0.000286	CcSEcCtD
Crizotinib—Diarrhoea—Capecitabine—kidney cancer	1.28e-05	0.000281	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.24e-05	0.000275	CcSEcCtD
Crizotinib—Dizziness—Capecitabine—kidney cancer	1.23e-05	0.000272	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—kidney cancer	1.2e-05	0.000265	CcSEcCtD
Crizotinib—Infection—Doxorubicin—kidney cancer	1.19e-05	0.000263	CcSEcCtD
Crizotinib—Vomiting—Capecitabine—kidney cancer	1.19e-05	0.000262	CcSEcCtD
Crizotinib—Shock—Doxorubicin—kidney cancer	1.18e-05	0.000261	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—kidney cancer	1.18e-05	0.00026	CcSEcCtD
Crizotinib—Rash—Capecitabine—kidney cancer	1.18e-05	0.000259	CcSEcCtD
Crizotinib—Dermatitis—Capecitabine—kidney cancer	1.17e-05	0.000259	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—kidney cancer	1.17e-05	0.000258	CcSEcCtD
Crizotinib—Nausea—Capecitabine—kidney cancer	1.11e-05	0.000244	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—kidney cancer	1.08e-05	0.000238	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—kidney cancer	1.07e-05	0.000236	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—kidney cancer	1.06e-05	0.000233	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—kidney cancer	1.04e-05	0.000231	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.04e-05	0.000229	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—kidney cancer	1.04e-05	0.000229	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—kidney cancer	1.03e-05	0.000227	CcSEcCtD
Crizotinib—Body temperature increased—Doxorubicin—kidney cancer	9.5e-06	0.00021	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—kidney cancer	8.62e-06	0.00019	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—kidney cancer	8.22e-06	0.000181	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—kidney cancer	7.95e-06	0.000175	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—kidney cancer	7.64e-06	0.000169	CcSEcCtD
Crizotinib—Rash—Doxorubicin—kidney cancer	7.58e-06	0.000167	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—kidney cancer	7.57e-06	0.000167	CcSEcCtD
Crizotinib—Nausea—Doxorubicin—kidney cancer	7.14e-06	0.000158	CcSEcCtD
Crizotinib—LCK—Disease—ERBB2—kidney cancer	2.56e-07	5e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—PIK3CA—kidney cancer	2.56e-07	5e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—CTNNB1—kidney cancer	2.56e-07	4.99e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC2A1—kidney cancer	2.54e-07	4.96e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PTEN—kidney cancer	2.54e-07	4.95e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—PIK3CA—kidney cancer	2.54e-07	4.95e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—kidney cancer	2.53e-07	4.95e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MTOR—kidney cancer	2.53e-07	4.93e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MAPK3—kidney cancer	2.53e-07	4.93e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—kidney cancer	2.53e-07	4.93e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—MAPK3—kidney cancer	2.53e-07	4.93e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—kidney cancer	2.52e-07	4.92e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—kidney cancer	2.52e-07	4.92e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—kidney cancer	2.51e-07	4.91e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—PIK3CA—kidney cancer	2.51e-07	4.91e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—kidney cancer	2.51e-07	4.9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KDR—kidney cancer	2.51e-07	4.89e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—kidney cancer	2.5e-07	4.89e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PTEN—kidney cancer	2.5e-07	4.88e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1B—kidney cancer	2.5e-07	4.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTEN—kidney cancer	2.49e-07	4.87e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—kidney cancer	2.48e-07	4.85e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—RAF1—kidney cancer	2.48e-07	4.85e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MAPK1—kidney cancer	2.48e-07	4.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—BRAF—kidney cancer	2.48e-07	4.84e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—kidney cancer	2.48e-07	4.83e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—RELA—kidney cancer	2.47e-07	4.82e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—MAPK3—kidney cancer	2.47e-07	4.81e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—kidney cancer	2.46e-07	4.8e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—kidney cancer	2.46e-07	4.8e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—ERBB2—kidney cancer	2.46e-07	4.79e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MAPK3—kidney cancer	2.45e-07	4.79e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—JUN—kidney cancer	2.45e-07	4.79e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—kidney cancer	2.45e-07	4.78e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP1A1—kidney cancer	2.45e-07	4.78e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—kidney cancer	2.45e-07	4.78e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—JUN—kidney cancer	2.45e-07	4.77e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—PIK3CA—kidney cancer	2.44e-07	4.75e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CTNNB1—kidney cancer	2.44e-07	4.75e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—CTNNB1—kidney cancer	2.43e-07	4.74e-06	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.42e-07	4.73e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MTOR—kidney cancer	2.42e-07	4.73e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—kidney cancer	2.42e-07	4.72e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MAPK1—kidney cancer	2.4e-07	4.69e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—MAPK1—kidney cancer	2.4e-07	4.69e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—kidney cancer	2.39e-07	4.66e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—JUN—kidney cancer	2.38e-07	4.65e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTEN—kidney cancer	2.37e-07	4.63e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1B—kidney cancer	2.37e-07	4.63e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PTEN—kidney cancer	2.37e-07	4.62e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CTNNB1—kidney cancer	2.36e-07	4.61e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—MAPK1—kidney cancer	2.35e-07	4.58e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—kidney cancer	2.34e-07	4.57e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MAPK1—kidney cancer	2.34e-07	4.56e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—PIK3CA—kidney cancer	2.32e-07	4.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HIF1A—kidney cancer	2.32e-07	4.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSC2—kidney cancer	2.32e-07	4.52e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APC—kidney cancer	2.31e-07	4.51e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KIT—kidney cancer	2.31e-07	4.51e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MAPK3—kidney cancer	2.31e-07	4.5e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTEN—kidney cancer	2.3e-07	4.5e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—PIK3CA—kidney cancer	2.3e-07	4.48e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—kidney cancer	2.29e-07	4.47e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—RAF1—kidney cancer	2.29e-07	4.47e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PIK3CA—kidney cancer	2.28e-07	4.45e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1B—kidney cancer	2.27e-07	4.44e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—kidney cancer	2.27e-07	4.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—kidney cancer	2.27e-07	4.43e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—kidney cancer	2.27e-07	4.43e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—kidney cancer	2.26e-07	4.41e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PIK3CA—kidney cancer	2.25e-07	4.39e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CTNNB1—kidney cancer	2.24e-07	4.37e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MTOR—kidney cancer	2.24e-07	4.37e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—kidney cancer	2.23e-07	4.36e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—kidney cancer	2.23e-07	4.34e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CRABP1—kidney cancer	2.22e-07	4.34e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KDR—kidney cancer	2.22e-07	4.33e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—kidney cancer	2.22e-07	4.33e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—kidney cancer	2.22e-07	4.33e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RAF1—kidney cancer	2.21e-07	4.32e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—kidney cancer	2.21e-07	4.31e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—kidney cancer	2.21e-07	4.31e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RELA—kidney cancer	2.2e-07	4.3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—kidney cancer	2.2e-07	4.29e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MAPK1—kidney cancer	2.2e-07	4.29e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—kidney cancer	2.19e-07	4.27e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTEN—kidney cancer	2.18e-07	4.26e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—kidney cancer	2.17e-07	4.25e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—BRAF—kidney cancer	2.17e-07	4.24e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK3—kidney cancer	2.17e-07	4.23e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—JUN—kidney cancer	2.17e-07	4.23e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MTOR—kidney cancer	2.16e-07	4.21e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PIK3CA—kidney cancer	2.15e-07	4.2e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTNNB1—kidney cancer	2.15e-07	4.19e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—kidney cancer	2.14e-07	4.18e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK3—kidney cancer	2.14e-07	4.17e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MAPK3—kidney cancer	2.13e-07	4.16e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTP1—kidney cancer	2.12e-07	4.14e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—kidney cancer	2.11e-07	4.12e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1B—kidney cancer	2.1e-07	4.1e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PTEN—kidney cancer	2.09e-07	4.09e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—kidney cancer	2.09e-07	4.07e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—kidney cancer	2.09e-07	4.07e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—kidney cancer	2.08e-07	4.06e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—kidney cancer	2.08e-07	4.06e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—kidney cancer	2.08e-07	4.06e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—kidney cancer	2.07e-07	4.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—kidney cancer	2.07e-07	4.04e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RAF1—kidney cancer	2.07e-07	4.04e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ITPR2—kidney cancer	2.07e-07	4.03e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK1—kidney cancer	2.06e-07	4.03e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RELA—kidney cancer	2.06e-07	4.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—kidney cancer	2.05e-07	4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KIT—kidney cancer	2.04e-07	3.99e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APC—kidney cancer	2.04e-07	3.99e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—kidney cancer	2.04e-07	3.97e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK1—kidney cancer	2.03e-07	3.97e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK3—kidney cancer	2.03e-07	3.96e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MAPK1—kidney cancer	2.03e-07	3.96e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—kidney cancer	2.03e-07	3.96e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1B—kidney cancer	2.03e-07	3.96e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK3—kidney cancer	2.02e-07	3.95e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MTOR—kidney cancer	2.02e-07	3.94e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—kidney cancer	2.02e-07	3.94e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—kidney cancer	1.98e-07	3.87e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—kidney cancer	1.98e-07	3.87e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—kidney cancer	1.97e-07	3.85e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK3—kidney cancer	1.97e-07	3.84e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—kidney cancer	1.95e-07	3.8e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—kidney cancer	1.95e-07	3.8e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—kidney cancer	1.95e-07	3.8e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—kidney cancer	1.93e-07	3.77e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—kidney cancer	1.93e-07	3.77e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK1—kidney cancer	1.93e-07	3.77e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—JUN—kidney cancer	1.93e-07	3.77e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK1—kidney cancer	1.92e-07	3.75e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—kidney cancer	1.92e-07	3.75e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—kidney cancer	1.92e-07	3.75e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—kidney cancer	1.91e-07	3.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—kidney cancer	1.91e-07	3.74e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—kidney cancer	1.91e-07	3.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—kidney cancer	1.91e-07	3.72e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—kidney cancer	1.9e-07	3.7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—kidney cancer	1.88e-07	3.68e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ACHE—kidney cancer	1.88e-07	3.68e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK1—kidney cancer	1.87e-07	3.66e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK3—kidney cancer	1.87e-07	3.64e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—kidney cancer	1.87e-07	3.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—kidney cancer	1.86e-07	3.62e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1A1—kidney cancer	1.85e-07	3.61e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—kidney cancer	1.83e-07	3.56e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—kidney cancer	1.82e-07	3.56e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—kidney cancer	1.82e-07	3.55e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—kidney cancer	1.81e-07	3.54e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RAF1—kidney cancer	1.81e-07	3.54e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—kidney cancer	1.81e-07	3.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—kidney cancer	1.81e-07	3.52e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RELA—kidney cancer	1.8e-07	3.52e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—kidney cancer	1.79e-07	3.5e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—kidney cancer	1.79e-07	3.5e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—kidney cancer	1.79e-07	3.49e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK3—kidney cancer	1.79e-07	3.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SCARB1—kidney cancer	1.78e-07	3.48e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK1—kidney cancer	1.78e-07	3.47e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—kidney cancer	1.77e-07	3.45e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—kidney cancer	1.77e-07	3.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS1—kidney cancer	1.77e-07	3.45e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—kidney cancer	1.77e-07	3.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—kidney cancer	1.76e-07	3.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—kidney cancer	1.75e-07	3.41e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PSMD7—kidney cancer	1.73e-07	3.38e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—kidney cancer	1.73e-07	3.38e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—kidney cancer	1.71e-07	3.33e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK1—kidney cancer	1.7e-07	3.32e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—kidney cancer	1.69e-07	3.29e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—kidney cancer	1.68e-07	3.27e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—kidney cancer	1.67e-07	3.27e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—kidney cancer	1.67e-07	3.26e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—kidney cancer	1.66e-07	3.24e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK3—kidney cancer	1.65e-07	3.22e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BCHE—kidney cancer	1.64e-07	3.2e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—kidney cancer	1.63e-07	3.17e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—kidney cancer	1.63e-07	3.17e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.62e-07	3.17e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—kidney cancer	1.62e-07	3.16e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—kidney cancer	1.61e-07	3.14e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—kidney cancer	1.61e-07	3.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RAF1—kidney cancer	1.6e-07	3.13e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RELA—kidney cancer	1.6e-07	3.12e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK3—kidney cancer	1.59e-07	3.11e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—kidney cancer	1.59e-07	3.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—kidney cancer	1.58e-07	3.09e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—kidney cancer	1.58e-07	3.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—kidney cancer	1.58e-07	3.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—kidney cancer	1.57e-07	3.07e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK1—kidney cancer	1.57e-07	3.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—kidney cancer	1.57e-07	3.06e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—kidney cancer	1.57e-07	3.06e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.57e-07	3.06e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—kidney cancer	1.55e-07	3.03e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—kidney cancer	1.54e-07	3.01e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—kidney cancer	1.53e-07	2.99e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK1—kidney cancer	1.52e-07	2.96e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK3—kidney cancer	1.49e-07	2.91e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—kidney cancer	1.48e-07	2.9e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—kidney cancer	1.48e-07	2.88e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—kidney cancer	1.47e-07	2.87e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—kidney cancer	1.46e-07	2.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—kidney cancer	1.45e-07	2.83e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—kidney cancer	1.44e-07	2.81e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—kidney cancer	1.43e-07	2.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK1—kidney cancer	1.42e-07	2.77e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—kidney cancer	1.4e-07	2.74e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—kidney cancer	1.4e-07	2.73e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—kidney cancer	1.39e-07	2.71e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—kidney cancer	1.38e-07	2.7e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—kidney cancer	1.38e-07	2.69e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—kidney cancer	1.36e-07	2.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—kidney cancer	1.35e-07	2.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—kidney cancer	1.34e-07	2.62e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—kidney cancer	1.32e-07	2.57e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK3—kidney cancer	1.31e-07	2.55e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—kidney cancer	1.31e-07	2.55e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—kidney cancer	1.27e-07	2.49e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—kidney cancer	1.27e-07	2.48e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—kidney cancer	1.27e-07	2.48e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK1—kidney cancer	1.24e-07	2.43e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—kidney cancer	1.24e-07	2.41e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—kidney cancer	1.23e-07	2.4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—kidney cancer	1.22e-07	2.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—kidney cancer	1.2e-07	2.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—kidney cancer	1.19e-07	2.33e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—kidney cancer	1.17e-07	2.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK3—kidney cancer	1.16e-07	2.26e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.14e-07	2.22e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—kidney cancer	1.13e-07	2.2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK1—kidney cancer	1.1e-07	2.15e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—kidney cancer	1.1e-07	2.14e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—kidney cancer	1.08e-07	2.11e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—kidney cancer	1.04e-07	2.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—kidney cancer	1.04e-07	2.03e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—kidney cancer	9.58e-08	1.87e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—kidney cancer	9.55e-08	1.86e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—kidney cancer	9.24e-08	1.8e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—kidney cancer	8.96e-08	1.75e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—kidney cancer	8.48e-08	1.66e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—kidney cancer	6.77e-08	1.32e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—kidney cancer	6.76e-08	1.32e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—kidney cancer	5.9e-08	1.15e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	4.16e-08	8.13e-07	CbGpPWpGaD
